TORONTO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Celestica Inc. (TSX: CLS) (NYSE: CLS), a leader in design, manufacturing, hardware platform and supply chain solutions for the world's most innovative companies, today announced that its Johor, Malaysia operation was honoured with a 2024 Supplier Excellence Award from Lam Research, a global provider of innovative wafer fabrication equipment and services to the semiconductor industry. Recognized from Lam's ecosystem of thousands of suppliers worldwide, Celestica wa ...

Celestica (NYSE: CLS ) has declined by 6.4% since my initial coverage, which was bullish . My updated analysis of CLS suggests that the share price pullback has nothing to do with the company's fundamentals. Celestica's financial As an investor who started my path five years ago with my own capital, I represent a blend of hands on experience and academic background in corporate finance. Due to my relatively young age I thrive on discovering long-duration growth opportunities and actively seek out opportunit ...

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Celestica (CLS), and highlights the importance of using these recommendations in conjunction with other analytical tools like the Zacks Rank. Group 1: Brokerage Recommendations - Celestica has an average brokerage recommendation (ABR) of 1.57, indicating a position between Strong Buy and Buy, based on recommendations from seven brokerage firms [2] - Of the seven recommendations, four are Strong Buy and two are Buy, which account for 57.1% and 28.6% of all recommendations respectively [2] - Despite the positive ABR, relying solely on this information for investment decisions may not be advisable, as studies show brokerage recommendations often fail to guide investors effectively [3] Group 2: Analyst Bias and Limitations - Analysts from brokerage firms tend to exhibit a strong positive bias in their ratings, often issuing five "Strong Buy" recommendations for every "Strong Sell" [4] - This bias indicates a misalignment of interests between brokerage firms and retail investors, which can lead to misleading insights regarding stock price movements [5][8] Group 3: Zacks Rank vs. ABR - The Zacks Rank is a proprietary tool that classifies stocks based on earnings estimate revisions, providing a more reliable indicator of near-term price performance compared to ABR [6][9] - Unlike ABR, which is based solely on brokerage recommendations, the Zacks Rank is updated frequently to reflect changes in earnings estimates, making it a timely tool for predicting future price movements [10] Group 4: Current Performance and Outlook for Celestica - The Zacks Consensus Estimate for Celestica's current year earnings remains unchanged at $3.65, suggesting steady analyst views on the company's earnings prospects [11] - The recent consensus estimate change, along with other factors, has resulted in a Zacks Rank of 3 (Hold) for Celestica, indicating a cautious approach despite the Buy-equivalent ABR [12]

In the latest trading session, Celestica (CLS) closed at $49.99, marking a +0.73% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.25% for the day. At the same time, the Dow added 0.2%, and the tech-heavy Nasdaq gained 0.56%. Coming into today, shares of the electronics manufacturing services company had lost 2.69% in the past month. In that same time, the Computer and Technology sector lost 0.11%, while the S&P 500 gained 1.65%. Market participants will be closely fo ...

Celestica (CLS) ended the recent trading session at $46.83, demonstrating a -0.34% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.29%. At the same time, the Dow lost 0.25%, and the tech-heavy Nasdaq lost 0.31%. The electronics manufacturing services company's shares have seen a decrease of 13.03% over the last month, not keeping up with the Computer and Technology sector's loss of 1.17% and the S&P 500's gain of 1.57%. The investment community wi ...

In the latest market close, Celestica (CLS) reached $45.55, with a +0.51% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.75%. On the other hand, the Dow registered a gain of 0.58%, and the technology-centric Nasdaq increased by 1%. The electronics manufacturing services company's stock has dropped by 13.3% in the past month, falling short of the Computer and Technology sector's gain of 2.48% and the S&P 500's gain of 4.03%. Market participants will b ...

Leveraging solid demand trends driven by healthy AI traction, Celestica Inc. (CLS) has surged 77.4% over the past year compared with the industry's growth of 10.9%. It has outperformed peers like Flex Ltd. (FLEX) and Jabil Inc. (JBL) over this period. Celestica is among the lesser-known winners of the artificial intelligence (AI) revolution. This Toronto, Canadabased company offers a one-stop shop for the electronics market, from design to manufacture to supply chain management, operating primarily as a beh ...

Celestica (CLS) closed the latest trading day at $46.65, indicating a +0.43% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 0.16%. On the other hand, the Dow registered a gain of 0.09%, and the technology-centric Nasdaq decreased by 0.3%. The electronics manufacturing services company's stock has dropped by 1.34% in the past month, falling short of the Computer and Technology sector's gain of 1.63% and the S&P 500's gain of 3.64%. Investors will be e ...

- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside's Proprietary SCS Microinjector® - - Topline Data Expected to be Reported During the Week of October 7, 2024 - ALPHARETTA, Ga., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced the completion of the final participant visit in the Company's ODY ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task. That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss. However, the task of finding cutting-edge growth stocks ...